Back

Assessing and treating 'residual risk' beyond low-density lipoproteins - discussion

31 August 2026 (09:27 - 09:45)
Organised by: Logo
Congress Presentation Part of: Assessing and treating 'residual risk' beyond low-density lipoproteins Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

4 More presentations in this session

Presentation thumbnail
Optimal ways to identify high-risk cohorts beyond low-density lipoproteins: unmet high-risk patients
Doctor P. Ridker (Boston, US)
Slides Video
Presentation thumbnail
Targeting lipoprotein(a)
Professor B. Nordestgaard (Copenhagen, DK)
Slides Video
Presentation thumbnail
Colchicine: who benefits?
Doctor J. Tardif (Montreal, CA)
Slides Video
Presentation thumbnail
GLP1 agonist: for everyone?
Professor E. Michos (Baltimore, US)
Slides Video

Access the full session

Session thumbnail
Assessing and treating 'residual risk' beyond low-density lipoproteins
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 09:27 CET
You may be interested in
thumbnail
Congress Presentation
Frontiers in anti-inflammatory therapies - discussion
29 August 2026
thumbnail
Congress Presentation
Everything you wanted to know about lipoprotein(a) - discussion
30 August 2026
thumbnail
Congress Presentation
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options – discussion.
29 August 2022
thumbnail
Congress Presentation
New insights into genetic and molecular mechanisms regulating atherosclerosis - discussion
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources